Current treatment paradigms and emerging therapies for NAFLD/NASH
Frontiers in Bioscience · 2021 · 26 (2) · 206-237
DOI: 10.2741/4892 ↗At a glance
Übersichtsarbeit in Frontiers in Bioscience, 2021. Written by Sana Raza and 4 co-authors. Institution: Department of Endocrinology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India. Cited 286 times so far (Crossref). The full text is freely available in PubMed Central. Funded by: Wellcome Trust, DBT-Wellcome Trust India Alliance.
Abstract (original language)
Non-alcoholic fatty liver disease (NAFLD) is one the fastest emerging manifestations of the metabolic syndrome worldwide. Non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD, may culminate into cirrhosis and hepatocellular cancer (HCC) and is presently a leading cause of liver transplant. Although a steady progress is seen in understanding of the disease epidemiology, pathogenesis and identifying therapeutic targets, the slowest advancement is seen in the therapeutic field. Currently, there is no FDA approved therapy for this disease and appropriate therapeutic targets are urgently warranted. In this review we discuss the role of lifestyle intervention, pharmacological agents, surgical approaches, and gut microbiome, with regard to therapy for NASH. In particular, we focus the role of insulin sensitizers, thyroid hormone mimetics, antioxidants, cholesterol lowering drugs, incretins and cytokines as therapeutic targets for NASH. We highlight these targets aiming to optimize the future for NASH therapy.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Department of Endocrinology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.
- Department of Endocrinology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, anthony.rohit@gmail.com.
Funding
- Wellcome Trust
- DBT-Wellcome Trust India Alliance
Cite
APA
Raza, S., Rajak, S., Upadhyay, A., Tewari, A., & Anthony Sinha, R. (2021). Current treatment paradigms and emerging therapies for NAFLD/NASH. Frontiers in Bioscience, 26(2), 206-237. https://doi.org/10.2741/4892
Vancouver
Raza S, Rajak S, Upadhyay A, Tewari A, Anthony Sinha R. Current treatment paradigms and emerging therapies for NAFLD/NASH. Frontiers in Bioscience. 2021;26(2):206-237. doi:10.2741/4892
BibTeX
@article{Raza2021,
author = {Raza, Sana and Rajak, Sangam and Upadhyay, Aditya and Tewari, Archana and Anthony Sinha, Rohit},
title = {Current treatment paradigms and emerging therapies for NAFLD/NASH},
journal = {Frontiers in Bioscience},
year = {2021},
volume = {26},
number = {2},
pages = {206--237},
doi = {10.2741/4892}
}
EUVIMED